# K110761

# 510(k) Summary

# MICT $\textcircled{8}$ TSH Using the MICT $\textsuperscript { \textregistered }$ Instrument

This summary of 510(k) safety and effectiveness is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

1. Submitter name, address, contact

MagnaBioSciences LLC 6325 Lusk Blvd. San Diego, CA 92121

Telephone: (858)481-4400   
Fax: (858-481-7410

Contact Person: James L. Wyatt

Date Prepared: February 2012

Device name

Proprietary name: MICT $\otimes$ TSH Using the ${ \bf M C T @ }$ Instrument   
Common name: Magnetic ImmunoChomatographyic Test for the determination of TSH

Classification Name:

Quantitative Determination of TSH in Human Serum

3. Predicate device

Qualigen FastPack® TSH (K052301)

4 Device description

The MICT $\textsuperscript { \textregistered }$ TSH Immunoassay for the quantitative determination of TSH in human serum is designed for use on MICT $\dot { \bigotimes }$ Instrument.

# MICT@ TSH Device Reagents

1. Solid phase nitrocellulose membrane device with two detection zones:

a. Control line region containing a polyclonal goat anti-rabbit IgG antibody, and   
b. Test line region containing a monoclonal anti-TSH antibody

# MagnaBioSciences, LLC

2. Lyophilized conjugate tube containing the monoclonal anti-TSH antibody covalently coupled to $3 0 0 \ \mathrm { n m }$ super paramagnetic particles.

The MICT $\otimes$ Immunoassay is a "sandwich" magnetic chromatographic assay:

Step 1: Sample or control $( 1 0 0 ~ \mu \mathrm { L } )$ is added to the lyophilized conjugate tube and mixed using an up and down motion in the pipet. Set 2: Transfer the entire contents of the sample/conjugate to the sample port on the nitrocellulose test cassette. Step 3: The sample/conjugate will chromatograph along the nitrocellulose membrane for 30 minutes, but not longer than 45 minutes after starting the test.. Step 4: Insert the test cassette into the MICT magnetic Instrument and press start after barcode is read. • Results will automatically print.

# 5. Intended use

The MICT® TSH is a magnetic lateral flow immunoassay for the in-vitro quantitative determination of TSH in human serum. The measurements of thyroid stimulating hormone (TSH) produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders. The MICT TSH immunoassay is designed for use with the MCIT instrument. The MICT System is intended for use in clinical laboratories.

6 Comparison to Predicate Device

The following tables compare the MICT $\textsuperscript { \textregistered }$ TSH with the Qualigen FastPack® TSH.

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>MICT TSH</td><td rowspan=1 colspan=1>FastPack® TSH</td></tr><tr><td rowspan=1 colspan=1>Intended Use.</td><td rowspan=1 colspan=1>The MICT® TSH is amagnetic lateral flowimmunoassay for the in-vitro quantitativedetermination of TSH inhuman serum. Themeasurements of thyroidstimulating hormone(TSH) produced by theanterior pituitary are usedin the diagnosis of thyroidor pituitary disorders. TheMICT System is intendedfor use in clinicallaboratories.</td><td rowspan=1 colspan=1>FastPack® TSH Immunoassayis a paramagnetic particleimmunoassay for the in-vitroquantitative determination ofTSH in human plasma. Themeasurements of thyroidstimulating hormone (TSH)produced by the anteriorpituitary are used in thediagnosis of thyroid orpituitary disorders. TheFastPack TSH Immunoassay isdesigned for use with theFastPack System</td></tr><tr><td rowspan=1 colspan=1>AssayMethodology:</td><td rowspan=1 colspan=1>Sandwich immunoassay</td><td rowspan=1 colspan=1>Sandwich immunoassay</td></tr><tr><td rowspan=1 colspan=1>StorageCondition:</td><td rowspan=1 colspan=1>1-30</td><td rowspan=1 colspan=1>2-8 °</td></tr><tr><td rowspan=1 colspan=1>Data Analysis</td><td rowspan=1 colspan=1>Internal data reduction viamicrocomputer</td><td rowspan=1 colspan=1>Internal data reduction viamicrocomputer</td></tr><tr><td rowspan=1 colspan=1>Test Processing</td><td rowspan=1 colspan=1>Semi-Automated</td><td rowspan=1 colspan=1>Semi-Automated</td></tr><tr><td rowspan=1 colspan=1>Sample Type:</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Plasma</td></tr><tr><td rowspan=1 colspan=1>Detector:</td><td rowspan=1 colspan=1>Magnetic Instrument</td><td rowspan=1 colspan=1>Photomultiplier Tube (PMT)</td></tr><tr><td rowspan=1 colspan=1>Label</td><td rowspan=1 colspan=1>Super Magnetic Particles</td><td rowspan=1 colspan=1>Alkaline Phosphatase-Lucegine</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>100 μL</td><td rowspan=1 colspan=1>100 μL</td></tr><tr><td rowspan=1 colspan=1>Assay Range</td><td rowspan=1 colspan=1>0.13 to 100 μIU/mL</td><td rowspan=1 colspan=1>0.13 to 100 μIU/mL</td></tr><tr><td rowspan=1 colspan=1>InstrumentRequired</td><td rowspan=1 colspan=1>MICT Instrument</td><td rowspan=1 colspan=1>Qualigen FastPack® System</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Monoclonal/Monoclonal</td><td rowspan=1 colspan=1>Monoclonal/Monoclonal</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Nitrocellulose Membrane</td><td rowspan=1 colspan=1>Magnetic Particles</td></tr><tr><td rowspan=1 colspan=1>Detection</td><td rowspan=1 colspan=1>Magnetic Moment</td><td rowspan=1 colspan=1>Chemiluminescence</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Factory generated mastercurve with singlecalibration per lot,calibration is stable untilexpiration of the assay lot.</td><td rowspan=1 colspan=1>Factory generated calibrationcurve using 6 standards.Recalibration required 14 dayat the customer site.</td></tr><tr><td rowspan=1 colspan=1>Throughput</td><td rowspan=1 colspan=1>Single Sample</td><td rowspan=1 colspan=1>Single Sample</td></tr><tr><td rowspan=1 colspan=1>Time to Result</td><td rowspan=1 colspan=1>30 minutes</td><td rowspan=1 colspan=1>15 minutes</td></tr><tr><td rowspan=1 colspan=1>ReagentsSupplied as</td><td rowspan=1 colspan=1>Box of 20 reagentcassettes with lyophilizedconjugate tubes.</td><td rowspan=1 colspan=1>Box of 50 individual Tests</td></tr></table>

Performance Characteristics:   

<table><tr><td>Periormance Characteristics: Feature</td><td></td><td>MICT@ TSH</td><td></td><td>FastPack® TSH</td></tr><tr><td>Precision</td><td colspan="2">Mean</td><td colspan="2">Mean</td></tr><tr><td rowspan="10"></td><td>μIU/mL</td><td>%CV</td><td>μIU/mL</td><td>%CV</td></tr><tr><td>Within Lab</td><td></td><td>Total Within Lab</td><td></td></tr><tr><td>Site 1</td><td></td><td></td><td></td></tr><tr><td>1 0.191</td><td>14.1</td><td>1</td><td>20.0</td></tr><tr><td>2 0.29 0.83</td><td>9.4</td><td>0.54 2</td><td>9.7</td></tr><tr><td>3</td><td>9.4</td><td>1.54 3 4.69</td><td>7.0</td></tr><tr><td>4</td><td>7.8</td><td>4 46.30</td><td>9.5</td></tr><tr><td>5</td><td>8.8</td><td></td><td></td></tr><tr><td>46.7 Site 2</td><td></td></tr><tr><td>1</td><td>13.3</td></tr><tr><td>2 3</td><td>0.29 10.1</td></tr><tr><td></td><td>0.87 7.8 4.1</td></tr><tr><td>4</td><td>9.1</td></tr><tr><td>5</td><td>9.5</td></tr><tr><td></td><td></td></tr><tr><td>Site 3 1 0.187 2</td><td>14.4</td></tr><tr><td></td><td>0.29 9.5</td></tr><tr><td></td><td>0.87 7.6</td><td></td></tr><tr><td></td><td>3.95 9.1</td><td></td></tr><tr><td>Sensitivity</td><td>48.4 7.5</td><td>Analytical = 0.043 μIU/mL</td></tr><tr><td></td><td>LOB = 0.04 μIU/mL LOD = 0.077 μIU/mL LOQ = 0.077 μIU/mL</td><td></td><td>Functional = 0.13 μIU/mL</td></tr><tr><td>Method Comparison</td><td></td><td></td><td>Three site performance evaluation of MiCT vs. Qualigen</td></tr><tr><td></td><td colspan="2"></td></tr><tr><td rowspan="9"></td><td rowspan="9">Site 1 : MICT = 0.97 FastPack -0.27 (n=66, r = 0.99)</td><td></td><td></td></tr><tr><td>FastPack TSH Method.</td><td></td></tr><tr><td></td><td></td></tr><tr><td></td></tr><tr><td>Site 2: MICT = 0.93 FastPack -0.07 (n=74, r = 0.99)</td></tr><tr><td>Site 3: MICT = 0.98 FastPack 0.00 (n=64, r = 0.99)</td></tr><tr><td></td></tr><tr><td>Pooled: MICT = 0.96 FastPack -0.12 (n=204, r = 0.99)</td></tr><tr><td></td></tr><tr><td rowspan="5">Substances Bilirubin Hemoglobin</td></tr><tr><td>No interference up to: 40 mg/dL</td><td>No interference up to:</td></tr><tr><td></td><td>40 mg/dL</td></tr><tr><td>1000 mg/dL</td><td>1000 mg/dL</td></tr><tr><td>3200 mg/dL 800 mg/dL</td><td>1000 mg/dL --</td></tr><tr><td>Phospholipid</td><td></td></tr><tr><td rowspan="3">Specificity</td><td rowspan="3">500 mlU/mL LH</td><td rowspan="3">n.d</td><td></td></tr><tr><td>500 mlU/mL LH</td></tr><tr><td>500 mlU/mL FSH 200,000 mlU/mL hCG</td></tr><tr><td colspan="2">500 mIU/mL FSH 200,000 mIU/mL hCG</td></tr></table>

MagnaBioSciences, LLC. c/o James Wyatt, PhD Chief Technical Officer 6325 Lusk Blvd. San Diego, CA 92121

Re: k110761 Trade Name: $\mathsf { M I C T } ^ { \mathfrak { B } }$ TSH and MICT® Instrument Regulation Number: 21 CFR $\ S 8 6 2 . 1 6 9 0$ Regulation Name: Thyroid Stimulating Hormone Test System Regulatory Class: II Product Codes: JLW, JJQ Dated: February 28, 2012 Received: March 6, 2012

Dear Dr. Wyatt:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). .

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

![](images/17964824bd754a76d90acb4a989f6043746f40c3f9a9f4dafb7a380a272a076f.jpg)

Coupney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use Form

510(k) Number: K110761

Device Name: MICT® TSH

Indications for Use:

The MICT® TSH is a magnetic lateral flow immunoassay for the in-vitro quantitative determination of TSH in human serum. The measurements of thyroid stimulating hormone (TSH) produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders. The MICT System is intended for use in clinical laboratories.

Concurrence of CDRH, Office of Device Evaluation (ODE)

![](images/830a997877848b09d92cef0b9c083628e9f422491feda24d78c761be13749643.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device Evaluation and Safety   
510(k)110761

Page 1 of 2

# Indications for Use Form

510(k) Number (if known): k110761

Device Name: MICT® Instrument

Indications for Use:

The MICT® TSH is a magnetic lateral flow immunoassay for the in-vitro quantitative determination of TSH in human serum. The measurements of thyroid stimulating hormone (TSH) produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders. The MICT System is intended for use in clinical laboratories.

Qnte Cheber